Published in J Clin Oncol on January 16, 2007
Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol (2013) 1.41
Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am (2008) 1.21
Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis. BMC Cancer (2012) 1.03
Primary diffuse large B-cell lymphoma of the ascending colon. Rare Tumors (2013) 0.97
NHL (diffuse large B-cell lymphoma). BMJ Clin Evid (2010) 0.91
Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. Korean J Hematol (2010) 0.90
Role of radiation therapy in localized aggressive lymphoma. J Clin Oncol (2007) 0.81
NHL (diffuse large B cell lymphoma). BMJ Clin Evid (2008) 0.80
Radiation treatment in older patients: a framework for clinical decision making. J Clin Oncol (2014) 0.80
Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future. Blood Lymphat Cancer (2012) 0.80
Analysis of treatment outcomes for primary tonsillar lymphoma. Radiat Oncol J (2016) 0.78
Primary sternum diffuse large B-cell lymphoma: A case report and review of the literature. Oncol Lett (2015) 0.78
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol (2016) 0.78
Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. Br J Haematol (2015) 0.78
Rituximab-including combined modality treatment for primary thyroid lymphoma: an effective regimen for elderly patients. Thyroid (2014) 0.78
Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. Blood Res (2014) 0.78
Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation. Int J Radiat Oncol Biol Phys (2015) 0.77
Risk factors and patterns of lymph node involvement in primary gastric large B-cell lymphoma: implications for target definition. Onco Targets Ther (2016) 0.75
A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma. Korean J Hematol (2011) 0.75
Consolidation Radiotherapy in Stage IE- IIE, Non-Bulky Primary Gastric Diffuse Large B-Cell Lymphoma with Post-Chemotherapy Complete Remission. PLoS One (2015) 0.75
Is Radiation Necessary for Treatment of Non-Hodgkin's Lymphoma of Bone? Clinical Results With Contemporary Therapy. Clin Orthop Relat Res (2016) 0.75
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood (2014) 0.75
Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option. Radiat Oncol (2016) 0.75
Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Exp Ther Med (2011) 0.75
Affluence and Private Health Insurance Influence Treatment and Survival in Non-Hodgkin's Lymphoma. PLoS One (2016) 0.75
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. Springerplus (2014) 0.75
The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma (2016) 0.75
Treatment outcome of diffuse large B-cell lymphoma involving the head and neck: Two-institutional study for the significance of radiotherapy after R-CHOP chemotherapy. Medicine (Baltimore) (2017) 0.75
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol (2003) 12.82
Follicular lymphoma international prognostic index. Blood (2004) 7.20
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol (2010) 5.20
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood (2007) 5.18
Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet (2007) 4.81
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med (2005) 4.13
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis (2014) 3.99
Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med (2005) 3.68
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 3.38
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood (2003) 3.37
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood (2010) 3.06
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol (2011) 2.97
Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients*. Crit Care Med (2014) 2.86
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol (2006) 2.82
High-altitude pulmonary edema at moderate altitude (< 2,400 m; 7,870 feet): a series of 52 patients. Chest (2003) 2.82
De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med (2014) 2.77
Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med (2012) 2.55
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol (2011) 2.40
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol (2011) 2.38
Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med (2007) 2.38
Renal effects of norepinephrine in septic and nonseptic patients. Chest (2004) 2.37
Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med (2004) 2.33
Outcome of acute mesenteric ischemia in the intensive care unit: a retrospective, multicenter study of 780 cases. Intensive Care Med (2015) 2.25
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol (2011) 2.20
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Risk factors for late-onset ventilator-associated pneumonia in trauma patients receiving selective digestive decontamination. Intensive Care Med (2004) 2.13
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood (2006) 2.09
Candida as a risk factor for mortality in peritonitis. Crit Care Med (2006) 2.07
Randomized controlled trial of sevoflurane for intubation in neonates. Paediatr Anaesth (2007) 2.06
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica (2007) 2.03
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood (2008) 1.98
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol (2013) 1.98
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med (2005) 1.95
MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood (2013) 1.95
Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res (2010) 1.95
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol (2010) 1.90
Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med (2003) 1.89
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood (2012) 1.89
Decompressive craniectomy for severe traumatic brain injury: Evaluation of the effects at one year. Crit Care Med (2003) 1.88
Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol (2006) 1.83
Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med (2013) 1.81
[Surviving sepsis: where we are today]. Presse Med (2006) 1.71
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol (2007) 1.70
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol (2012) 1.66
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol (2008) 1.65
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol (2009) 1.60
Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. Crit Care Med (2005) 1.60
Variable compliance with clinical practice guidelines identified in a 1-day audit at 66 French adult intensive care units. Crit Care Med (2012) 1.60
Tropheryma whipplei in patients with pneumonia. Emerg Infect Dis (2010) 1.59
Long-term (6-year) effect of selective digestive decontamination on antimicrobial resistance in intensive care, multiple-trauma patients. Crit Care Med (2003) 1.59
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol (2003) 1.58
Retention of Plasmodium falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleen. Blood (2008) 1.58
Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg (2004) 1.57
Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol (2009) 1.54
Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma (2013) 1.54
Outcome of postoperative pneumonia in the Eole study. Intensive Care Med (2003) 1.53
Influence on outcome of ventilator-associated pneumonia in multiple trauma patients with head trauma treated with selected digestive decontamination. Crit Care Med (2002) 1.53
Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. Leuk Lymphoma (2013) 1.49
Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness. Int J Cancer (2005) 1.48
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med (2012) 1.47